CFM
OBIO icon

Catalyst Funds Management’s Orchestra BioMed OBIO Stock Holding History

Catalyst Funds Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,644
Closed -$117K – 817
2026
Q1 		$117K Buy
+27,644
New +$118K 0.02% 481
2025
Q3 		– Sell
-11,400
Closed -$30.6K – 602
2025
Q2 		$30.6K Buy
+11,400
New +$33.3K 0.01% 403

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Catalyst Funds Management's OBIO Position: Q2 2026 in Review

Catalyst Funds Management sold out of Orchestra BioMed (OBIO) in Q2 2026, closing a stake of 27,644 shares — an estimated $117K sold.

Catalyst Funds Management first reported a position in OBIO in Q2 2025 and held it in 2 quarters. The position peaked at $117K in Q1 2026. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Catalyst Funds Management reported no remaining Orchestra BioMed position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 27,644 Orchestra BioMed shares in Q2 2026, an estimated $117K.
  • Catalyst Funds Management first reported a position in Orchestra BioMed in Q2 2025 and held it in 2 quarters.
  • Catalyst Funds Management's Orchestra BioMed position peaked at $117K in Q1 2026.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.